References

Mutations in AML: prognostic and therapeutic implications

10.1182/asheducation-2016.1.348 · 2016 · External reference

Genetic and epigenetic heterogeneity in acute myeloid leukemia

10.1016/j.gde.2016.03.011 · 2016 · External reference

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

10.1182/blood-2016-08-733196 · 2017 · External reference

Acute myeloid leukemia: 2019 update on risk-stratification and management

10.1002/ajh.25214 · 2018 · External reference

Acute myeloid leukaemia

10.1016/s0140-6736(18)31041-9 · 2018 · External reference

Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation

10.1056/nejmoa1614359 · 2017 · External reference

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

10.1056/nejmoa1902688 · 2019 · External reference

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)00464-6 · 2023 · External reference

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

10.1056/nejmoa1716984 · 2018 · External reference

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

10.1182/blood-2017-04-779405 · 2017 · External reference

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

10.1038/s41586-023-05812-3 · 2023 · External reference

Treatment for relapsed/refractory acute myeloid leukemia

10.1097/hs9.0000000000000572 · 2021 · External reference

How I treat refractory and relapsed acute myeloid leukemia

10.1182/blood.2023022481 · 2024 · External reference

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission

10.1200/jco.2011.40.5977 · 2013 · External reference

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial

10.1200/jco.2013.54.4973 · 2015 · External reference

Genomic classification and prognosis in acute myeloid leukemia

10.1056/nejmoa1516192 · 2016 · External reference

Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice

10.1038/ng.796 · 2011 · External reference

Mutant NPM1 maintains the leukemic state through HOX expression

10.1016/j.ccell.2018.08.005 · 2018 · External reference

Treatment of relapsed/refractory acute myeloid leukemia

10.1007/s11864-017-0456-2 · 2017 · External reference

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

10.1007/s00277-018-3304-y · 2018 · External reference

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

10.1182/bloodadvances.2022008316 · 2023 · External reference

More than 10% of NPM1-mutated AML relapses occur after 5 years from complete remission [abstract]

10.1182/blood-2018-99-113109 · 2018 · External reference

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

10.3324/haematol.2014.104133 · 2014 · External reference

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

10.1182/bloodadvances.2020003734 · 2021 · External reference

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

10.1007/s00277-020-03911-z · 2020 · External reference

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

10.1182/blood-2018-08-868752 · 2019 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study

10.1002/ajh.26039 · 2021 · External reference

Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study

10.1200/jco.18.01600 · 2019 · External reference

Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML

10.1200/jco.23.01911 · 2024 · External reference

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

10.1038/s41408-025-01353-2 · 2025 · External reference

Unresolved reference

2025 · External reference

Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia

10.1158/2159-8290.cd-22-0366 · 2023 · External reference

NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

10.1002/ajh.26989 · 2023 · External reference

Deregulation of the HOXA9/MEIS1 axis in acute leukemia

10.1097/moh.0000000000000245 · 2016 · External reference

Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development

10.1016/j.ccell.2016.05.008 · 2016 · External reference

DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

10.1038/onc.2015.359 · 2016 · External reference

Large conserved domains of low DNA methylation maintained by Dnmt3a

10.1038/ng.2836 · 2014 · External reference

Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus

10.1182/blood-2004-12-4664 · 2005 · External reference

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

10.1038/embor.2011.43 · 2011 · External reference

CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex

10.1038/s41375-019-0382-3 · 2019 · External reference

NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis

10.1016/j.ccell.2016.10.019 · 2016 · External reference

Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia

10.1158/2159-8290.cd-22-0424 · 2023 · External reference

NPM1-mutated acute myeloid leukemia: from bench to bedside

10.1182/blood.2019004226 · 2020 · External reference

The menin inhibitor ziftomenib (KO-539) synergizes with agents targeting chromatin regulation or apoptosis and sensitizes AML with MLL rearrangement or NPM1 mutation to venetoclax [abstract]

10.1182/blood-2022-167566 · 2022 · External reference

Clinical-stage menin inhibitor KO-539 is synergistically active with multiple classes of targeted agents in KMT2A-r and NPM1-mutant AML models [abstract]

10.1182/blood-2021-149831 · 2021 · External reference

Preclinical in vivo activity of the menin inhibitor ziftomenib (KO-539) in pediatric KMT2A-rearranged acute lymphoblastic leukemia [abstract]

10.1182/blood-2022-157225 · 2022 · External reference

Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA Registry Experience

10.3390/cancers14071734 · 2022 · External reference

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

10.1016/s2352-3026(20)30210-6 · 2020 · External reference

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia

10.3324/haematol.2024.286589 · 2025 · External reference

Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents

10.1080/10428194.2022.2113530 · 2022 · External reference

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

10.3324/haematol.2020.252569 · 2021 · External reference

Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies

10.1111/ejh.13527 · 2021 · External reference

Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax

10.1016/j.leukres.2022.106942 · 2022 · External reference

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

10.3324/haematol.2022.282677 · 2023 · External reference

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

10.1002/ajh.27246 · 2024 · External reference

Ziftomenib in relapsed or refractory NPM1-mutated AML

10.1200/jco-25-01694 · 2025 · External reference

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study

10.1038/s41408-025-01344-3 · 2025 · External reference

Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)

10.1200/jco.23.01599 · 2024 · External reference

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

10.1016/s1470-2045(24)00386-3 · 2024 · External reference

Hematologic recovery from venetoclax-containing regimens in relapsed/refractory acute myeloid leukemia patients depending on prior allogeneic hematopoietic cell transplantation [abstract]

10.1182/blood-2019-125377 · 2019 · External reference

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

10.1182/blood.2025028357 · 2025 · External reference

Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML

10.1200/jco-25-00914 · 2025 · External reference

Menin inhibitors: new targeted therapies for specific genetic subtypes of difficult-to-treat acute leukemias

10.3390/cancers17010142 · 2025 · External reference

Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)

10.1200/jco.24.00826 · 2025 · External reference

Targeting menin in acute myeloid leukemia: therapeutic advances and future directions

10.3390/cancers16223743 · 2024 · External reference

Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting

10.1186/s13045-025-01718-x · 2025 · External reference

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure

10.1111/bjh.18887 · 2023 · External reference

Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand

10.1177/20406207251372770 · 2025 · External reference

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

10.1182/bloodadvances.2023011106 · 2024 · External reference

Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients

10.3390/cancers14082025 · 2022 · External reference